Apixaban

Intervention Approved 2011

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country
139 trials, 49 with no results posted

Funders: Cancer Council NSW and 2 more
53 of 139 trials sponsored by its developers

Humans1

Associations

Dementia

downin humans1HR 0.79

1 study

Apixaban lowers the risk of dementia in humans (HR 0.79, 95% CI 0.64-0.96).
Humansin atrial fibrillation, compared to dabigatrann = 21,671
Oral anticoagulant use and incident dementia in atrial fibrillation by baseline LIBRA score: a population-based cohort study using the 45 and up study
GeroScience8 Aug 2026

Trials

139

Approved

EMA Eliquis
18 May 2011Arthroplasty, Venous Thromboembolism, Atrial Fibrillation, Diabetes Mellitus, Embolism, Heart Failure, Pulmonary Embolism, Stroke, Deep Vein Thrombosis, hypertension
FDA Eliquis
28 Dec 2012Atrial Fibrillation, Embolism, Pulmonary Embolism, Stroke, Venous Thromboembolism, Deep Vein Thrombosis
EMA Apixaban Accord
23 Jul 2020Venous Thromboembolism, Stroke, Arthroplasty, Diabetes Mellitus, Embolism, Heart Failure, Pulmonary Embolism, Deep Vein Thrombosis, Non-valvular Atrial Fibrillation, hypertension
FDA Eliquis, Eliquis Sprinkle
17 Apr 2025
FDA Apixaban

Repurposing

Dementia
Phase 4Recruiting1 trial
Coronary artery disease
Phase 4Active, not recruiting1 trial
Ischemic stroke
Phase 4Recruiting5 trials
COVID-19
Phase 4Completed2 trials
Cerebral small vessel disease
Phase 3Completed1 trial
Acute myocardial infarction
Phase 4Recruiting1 trial

40 of 55

Transient ischemic attack
Phase 3Results posted1 trial
Liver disease
Phase 4Recruiting2 trials
Fibrosis
Phase 4Completed3 trials
Periodontal disease
Phase 3Completed1 trial
Neoplasm
Phase 4Completed4 trials
Multiple myeloma
Phase 4Results posted2 trials
Aortic valve stenosis
Phase 3Completed3 trials
Thrombosis
Phase 4Results posted10 trials
Cerebral infarction
Phase 4Recruiting1 trial
Subarachnoid hemorrhage
Phase 3Completed1 trial
Lymphoma
Phase 3Results posted1 trial
Hematologic neoplasms
Phase 3Results posted1 trial
Thromboembolism
Phase 4Results posted5 trials
Atrial flutter
Phase 3Results posted2 trials
Intracranial hemorrhage
Phase 3Completed2 trials
Chronic limb-threatening ischemia
Phase 3Status unknown1 trial
Renal insufficiency
Phase 3Terminated1 trial
Varicose veins
Phase 4Recruiting1 trial
Venous thrombosis
Phase 4Results posted18 trials
Cerebral hemorrhage
Phase 3Completed3 trials
Aortic valve disease
Phase 3Terminated1 trial
Hepatic encephalopathy
Phase 4Recruiting1 trial
Portal hypertension
Phase 4Completed2 trials
Antiphospholipid syndrome
Phase 4Completed1 trial
Ascites
Phase 4Recruiting1 trial
Mesenteric ischemia
Phase 3Results posted1 trial
Right ventricular dysfunction
Phase 4Terminated1 trial
Hepatocellular carcinoma
Phase 2Status unknown1 trial
Acute coronary syndrome
Phase 2Results posted3 trials
Liver cirrhosis
Phase 2Recruiting2 trials
Spinal cord injury
Phase 2Terminated1 trial
Cholangiocarcinoma
Phase 2Status unknown1 trial
Essential thrombocythemia
Phase 2Completed1 trial
Glioblastoma
Phase 2Recruiting1 trial

In trials

Hemorrhage
Phase 4Recruiting5 trials
Chronic kidney failure
Phase 4Results posted4 trials
Hemostatic Disorders
Phase 4Status unknown3 trials
Anticoagulation
Phase 4Results posted2 trials
Left Ventricular Thrombus
Phase 4Recruiting2 trials
Kidney transplant
Phase 4Completed1 trial

All 14

Pharmacokinetic
Phase 4Completed1 trial
Intracranial Thrombosis
Phase 3Results posted2 trials
Neoplasm metastasis
Phase 3Results posted2 trials
Precursor cell lymphoblastic leukemia lymphoma
Phase 3Results posted1 trial
Subdural hematoma
Phase 3Completed1 trial
Stomach neoplasm
Phase 2Status unknown1 trial
N a healthy subject
Phase 1Completed2 trials
Fasting
Early phase 1Completed1 trial

Readouts due

15 Apr 2027
Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
Recruiting
1 Oct 2027
Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)
Phase 4Active, not recruiting

Stopped

NCT02945280TerminatedVenous thromboembolism
COVID-19 resource allocation
NCT03678506TerminatedVenous thromboembolism
The study was interrupted after a planned interim analysis for the high rate of primary outcomes (7.3%; 95% confidence interval \[CI\], 4.5-11.2)
NCT03988842TerminatedPulmonary embolism
COVID-19 pandemic
NCT04142658TerminatedAortic valve stenosis
Safety
NCT02664155TerminatedRenal insufficiency
recruiting difficulties
NCT00852397TerminatedAcute coronary syndrome
See termination reason in detailed description.

All 7

NCT03200613TerminatedSpinal cord injury
study not feasible due to too slow recruitment

Trial sponsors

Bristol Myers Squibb
Company27 trialsPhase 456,020 people
Pfizer
Company6 trialsPhase 41,991 people
Artivion
Company1 trialPhase 3863 people
Portola Pharmaceuticals
Company3 trialsPhase 2315 people
Janssen Research & Development
Company1 trialPhase 2308 people
Perosphere Pharmaceuticals
Company1 trialPhase 260 people
Scotmann Pharmaceuticals
Company1 trialPhase 240 people
VarmX
Company2 trialsPhase 1145 people

Latest

1 in 12 months

GeroScience8 Aug

Oral anticoagulant use and incident dementia in atrial fibrillation by baseline LIBRA score: a population-based cohort study using the 45 and up study

Cohort study of 21,671 peopleAtrial fibrillation

Paper